World Market for Addiction Disorders, 2009-2016

The Future Therapies for Substance Dependence and Impulse Control

Publication Date	October 2009
Publisher	URCH Publishing
Product Type	Report
Pages	81
ISBN Number	not applicable
Product Code	URC00031

Buy this product or for assistance call +44 20 7060 7474

PDF £1,495.00$2487 | €1673

PRINT £1,525.00$2537 | €1707

FAX Order above formats by FAX

Summary

A comprehensive update of the 2005 edition

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion

The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.

The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.

The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.

Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.

Objectives of Report

The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Report Highlights Include:

The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
Review of epidemiological, aetiological, and demographic data for addiction disorders
Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
Sales estimates (US$) to 2012 for major therapy areas
Strategic insights for life-cycle optimization and product development
Critical evaluation of leading addiction pharmacotherapies
Emerging markets identified and sector analysis
Trend analysis of industry events and activities over past 2 years
Detailed R&D themes and clusters by addiction area
Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
High revenue-yielding prospects identified with projected sales estimations
R&D pipeline positioning for novel candidates
Market insights for product development and drug promotion

What you can learn from this report:

Which addiction therapies are the current and potential future market leaders
How companies are reformulating products for addiction indications
Which premarket addiction pharmacotherapies are identified as high-value products
Which companies are developing drugs for addiction disorders
Sales predictions to 2016 for addiction pharmacotherapies
What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
Which addiction subsectors could be niche market opportunities
What the future outlook holds for addiction pharmacotherapies
Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
Which molecules and compounds are main R&D clusters for dependency disorders
Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025

Report Contains:

Detailed survey and analysis of the current and future global addiction disorder market
Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
Market analysis and insight of key addiction pharmacotherapies and pipelines
Market value predictions of individual marketed products to 2016
Insight and trend analysis of pipeline products for addiction disorders
Review of promising pipeline products and potential market opportunities
Extensive coverage of the R&D pipeline for addiction disorders
Guide to leads for potential licensing opportunities

Companies Mentioned in this Report include

Acrux
Alkermes
Biotie Therapies
Brookwood Pharmaceuticals
Catalyst Pharma Partners
Celtic Pharmaceuticals
Cephalon
Drug Abuse Sciences
Elbion
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Impax Laboratories
InterveXion Therapeutics
J&J
Janssen-Cilag
Krele Pharma
Merck Serono
Nabi Biopharmaceuticals
Pfizer
Sanofi-Aventis
Somaxon Pharma.
STADA
Synosia Therapeutics
Targacept
Teva Pharmaceuticals
Titan Pharmaceuticals
WorldMeds
Yaupon Therapeutics

Content

Chapter 1. Introduction to Addiction Disorders
- Addiction: Substance Characteristics and Prevalence of Misuse
- Neurobiological Basis of Addiction
- Prevalence of Substance Misuse - Estimates for North America, Europe and Asia
  - North America
  - United States
  - Canada
  - Europe
  - Asia (Japan)
- Incidence Estimates for Addiction Disorders in North America, Europe, and Japan
- Treatment Options
Chapter 2. The Addiction Pharmacotherapy Market
- Market Overview for Addiction Disorders
- Market Forecasts by Therapeutic Area
  - Alcohol Addiction
  - Narcotic Addiction
  - Tobacco Addiction
Chapter 3. Alcohol Addiction Market
- Alcohol Addiction
  - Acamprosate (Campral) - Merck Serono/Forest Laboratories
  - Disulfiram (Antabuse) - Alpharma
  - Naltrexone Hydrochloride
  - Alkermes - Reformulated Naltrexone (Vivitrol)
- Pipeline Focus for Alcohol Addiction - Biotie Therapies Corp
  - Nalmefene
  - Naltrexone Depot
- Alcohol Addiction - Market Insights and Future Considerations
Chapter 4. The Narcotic Addiction Market
- Global Narcotics - Usage Statistics
- Narcotic Addiction - The Scale of the Problem
- Pharmacotherapies for Narcotic Addiction - Market Evaluation
- Opioid Addiction Pharmacotherapies
  - Drug Substitute Therapies
  - Subutex/Suboxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
  - Suboxone Reformulation
  - Methadone
- Drugs to Control Opioid Withdrawal Symptoms
  - BritLofex (Lofexidine); Opizone (Naltrexone) - Britannia Pharma/STADA
  - Naltrexone
  - Nalorex - Bristol-Myers Squibb
  - Opizone - Britannia
- Therapeutic Switching in Addiction Markets
- Outlook for Pharmacotherapeutic Markets Related to Alcohol and Narcotic Abuse
Chapter 5. Tobacco Addiction
- Prevalence and Mortality Statistics
- Nicotine: Mechanism of Action
- Tobacco Dependence and Smoking Cessation
- Smoking and Health Consequences
  - Healthcare Costs of Smoking Addiction
- Tobacco Addiction Pharmacotherapeutics
- Market Analysis of Smoking Cessation Pharmacotherapeutics
- Nicotine Replacement Therapies
- Nicorette/Nicotrol - McNeil Healthcare/Johnson & Johnson
- Sales Estimates
  - NiQuitin/NicoDerm/Nicorette/Nicabate - GlaxoSmithKline
  - Sales Estimates
  - Nicotinell/Habitrol - Novartis
  - Sales Estimates
  - Neuromodulating Pharmacotherapies for Smoking Cessation
  - Zyban (Bupropion) - GlaxoSmithKline
  - Sales Estimates
  - Champix/Chantix (Varenicline) - Pfizer
  - Sales Estimates
- Tobacco Addiction - Market Insights and Future Considerations
Chapter 6. Drugs in Research and Development
- Addiction Disorders - Research and Development Overview
- Pipeline Addiction Pharmacotherapies
- Alcohol Dependence
- Cocaine Dependence
- Novel Late-Stage Candidates
  - Celtic Pharmaceuticals
  - Synosia Therapeutics/Roche
  - Cannabis Dependence
  - Immunotherapy Focus - InterveXion Therapeutics
- Opioid Dependence
  - Late-Stage Development Products for Opioid Dependence
- Impulse Control Disorders
- Pipeline Focus - Gambling Addiction
- Tobacco/Nicotine Dependence
- Pipeline Focus on Immunotherapies for Tobacco Dependence
  - Nabi Biopharmaceuticals - NicVAX
  - Celtic Pharmaceuticals - TA-NIC
- Smoking Cessation - A Transforming Market
Chapter 7. Market Analysis, Therapy Forecasting, and Prospect Mining
- Market Analysis and Therapy Forecasting
- Therapy Area Forecasts
  - Comparative Analysis: Addiction Pharmacotherapies
- Prospect Mining
  - Addiction Disorder Pharmacotherapy Prospects
- Therapy Area Forecasts 2016 and 2025
Chapter 8. Summary and Key Data Points on the Addiction Market
- Key Data Points
- Reference Sources
List of Tables
- Table 1.1 Neurotransmitter Systems Associated with Addiction
- Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
- Table 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009 (000' users)
- Table 1.4 Estimated Incidence for Addiction Disorders in North America, Europe and Japan, 2009 (incidence in 000s)
- Table 2.1 Market Synopsis for Addiction Disorders: Current data
- Table 2.2 Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2008-2016
- Table 3.1 Physiological Consequences of the Disulfiram-Alcohol Reaction
- Table 5.1 Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2008-2016
- Table 6.1 Drugs in Development/Trials for Alcohol Dependence, 2009
- Table 6.2 Drugs in Development/Trials for Cocaine Dependence, 2009
- Table 6.3 Drugs in Development/Trials for Cannabis Dependence, 2009
- Table 6.4 Drugs in Development/Trials for Ampetamine and Phencyclidine Dependencies, 2009
- Table 6.5 Drugs in Development/Trials for Opioid Dependence, 2009
- Table 6.6 Drugs in Development/Trials for Impulse Control Disorders, 2009
- Table 6.7 Drugs in Development/Trials for Tobacco Addiction, 2009
- Table 7.1 Estimated Global Drug Market (US$m) and Growth Rate (%) for Addiction Pharmacotherapies, 2008-2016
- Table 7.2 Therapy Area Forecasts for the World Addiction Disorders Market, 2016 and 2025
List of Figures
- Figure 1.1 Estimated Prevalence of Substance Misuse in United States, 2009
- Figure 1.2 stimated Prevalence of Substance Misuse in Canada, 2009
- Figure 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009
- Figure 1.4 Estimated Prevalence of Substance Misuse in Japan, 2009
- Figure 2.1 Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2008-2016
- Figure 2.2 Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 2009 & 2016
- Figure 7.1 Comparative Analysis of Leading Addiction Pharmacotherapies, 2008-2016 (US$m)
- Figure 7.2 Key Addiction Disorder Pharmacotherapy Prospects, 2009